Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/17/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. AMZN
10. META

Go back to Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa
(NASDAQ: SYRE) Delayed: 92.68 +1.51 (1.66%)
Previous Close $91.17    52 Week High $ 
Open $92.86    52 Week Low $ 
Day High $95.19    P/E N/A 
Day Low $91.14    EPS $ 
Volume 1,438,923